title: We need both randomized trials and real-world data: the example of everolimus as second-line therapy for mRCC.
authors.affiliation: UOC di Oncologia, Azienda Ospedaliera 'A. Cardarelli', Naples, Italy.
authors.forename: Mimma
authors.initials: M
authors.lastname: Rizzo
authors.forename: Giacomo
authors.initials: G
authors.lastname: Cartenì
authors.forename: Giovanni
authors.initials: G
authors.lastname: Pappagallo
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D015331:Cohort Studies; D000068338:Everolimus; D019317:Evidence-Based Medicine; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D064887:Observational Studies as Topic; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D000068338:Everolimus; D020123:Sirolimus
keywords: everolimus; mRCC; observational studies; randomized trials; second-line therapy